Second-Line Chemotherapy

DRUG4 trials

Sponsors

Hoffmann-La Roche, Medical College of Wisconsin, Sun Yan, Fudan University

Conditions

Colon Rectal Cancer AdenocarcinomaHead and Neck NeoplasmsImmunotherapyNon-Squamous Non-Small Cell Lung CancerPancreatic CancerPeritoneal (Metastatic) CancerRadiation TherapySecond-line Treatment

Phase 2

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

RecruitingNCT03322995

Medical College of WisconsinPancreatic Cancer

Start: 2018-06-21End: 2032-06-01Target: 125Updated: 2026-01-08

Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors

Sun YanHead and Neck Neoplasms

Start: 2019-07-29End: 2022-06-30Target: 53Updated: 2020-10-23

Phase 3

A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy

CompletedNCT01328951

Hoffmann-La RocheNon-Squamous Non-Small Cell Lung Cancer

Start: 2011-09-30End: 2016-01-31Updated: 2016-10-28

FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)

Not yet recruitingNCT07815834

Fudan UniversityColon Rectal Cancer Adenocarcinoma, Immunotherapy, Peritoneal (Metastatic) Cancer +2

Start: 2026-09-01End: 2031-03-01Target: 198Updated: 2026-09-11